These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 26693105)

  • 1. Anticoagulant properties of enoxaparin 400 IU/mL-40 % ethanol catheter lock solution.
    Calvet L; Piot M; Lartigue C; Souweine B; Tardy-Poncet B
    Springerplus; 2015; 4():746. PubMed ID: 26693105
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Compatibility of Injectable Anticoagulant Agents in Ethanol; In Vitro Antibiofilm Activity and Impact on Polyurethane Catheters of Enoxaparin 400 U/mL in 40% v/v Ethanol.
    Balestrino D; Quintana M; Charbonnel N; Forestier C; Lartigue C; Souweine B
    PLoS One; 2016; 11(7):e0159475. PubMed ID: 27441664
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of a novel point-of-care enoxaparin monitor with central laboratory anti-Xa levels.
    Saw J; Kereiakes DJ; Mahaffey KW; Applegate RJ; Braden GA; Brent BN; Brodie BR; Groce JB; Levine GN; Leya F; Moliterno DJ
    Thromb Res; 2003; 112(5-6):301-6. PubMed ID: 15041274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thrombotic reactant markers in non-ST segment elevation acute coronary syndromes treated with either enoxaparin (low molecular weight heparin) or unfractionated heparin.
    Gurfinkel E; Duronto E; Colorio C; Bozovich G; Cohen M; Mautner B
    J Thromb Thrombolysis; 1999 Oct; 8(3):227-32. PubMed ID: 10500313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The low molecular weight heparin, enoxaparin, limits infarct size at reperfusion in the dog.
    Libersan D; Khalil A; Dagenais P; Quan E; Delorme F; Uzan A; Latour JG
    Cardiovasc Res; 1998 Mar; 37(3):656-66. PubMed ID: 9659449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Percutaneous coronary intervention in patients receiving enoxaparin or unfractionated heparin after fibrinolytic therapy for ST-segment elevation myocardial infarction in the ExTRACT-TIMI 25 trial.
    Gibson CM; Murphy SA; Montalescot G; Morrow DA; Ardissino D; Cohen M; Gulba DC; Kracoff OH; Lewis BS; Roguin N; Antman EM; Braunwald E;
    J Am Coll Cardiol; 2007 Jun; 49(23):2238-46. PubMed ID: 17560287
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of switching from either unfractionated heparin or enoxaparin to bivalirudin in patients with non-ST-segment elevation acute coronary syndromes managed with an invasive strategy: results from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial.
    White HD; Chew DP; Hoekstra JW; Miller CD; Pollack CV; Feit F; Lincoff AM; Bertrand M; Pocock S; Ware J; Ohman EM; Mehran R; Stone GW
    J Am Coll Cardiol; 2008 May; 51(18):1734-41. PubMed ID: 18452778
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of preoperative enoxaparin versus unfractionated heparin on bleeding indices in patients undergoing coronary artery bypass grafting.
    Kincaid EH; Monroe ML; Saliba DL; Kon ND; Byerly WG; Reichert MG
    Ann Thorac Surg; 2003 Jul; 76(1):124-8; discussion 128. PubMed ID: 12842525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early postoperative use of unfractionated heparin or enoxaparin is associated with increased surgical re-exploration for bleeding.
    Jones HU; Muhlestein JB; Jones KW; Renlund DG; Bair TL; Bunch TJ; Horne BD; Lappé DL; Anderson JL; Doty DB
    Ann Thorac Surg; 2005 Aug; 80(2):518-22. PubMed ID: 16039196
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the efficacy of an interdialytic "ethanol 40% v/v - enoxaparin 1000 U/mL" lock solution to prevent tunnelled catheter infections in chronic hemodialysis patients: a multi-centre, randomized, single blind, parallel group study.
    Aniort J; Piraud A; Adda M; Perreira B; Bouiller M; Fourcade J; Guerraoui A; Kalbacher E; Krumel T; Moragues HL; Thibaudin D; Vela CG; Vernin G; Weclawiak H; Bernard L; Heng AE; Souweine B
    BMC Nephrol; 2019 Apr; 20(1):149. PubMed ID: 31039759
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enoxaparin vs. unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction in elderly and younger patients: results from ExTRACT-TIMI 25.
    White HD; Braunwald E; Murphy SA; Jacob AJ; Gotcheva N; Polonetsky L; Antman EM
    Eur Heart J; 2007 May; 28(9):1066-71. PubMed ID: 17456482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the effect of fondaparinux and enoxaparin on thrombin generation during in-vitro clotting of whole blood and platelet-rich plasma.
    Gerotziafas GT; Depasse F; Chakroun T; Van Dreden P; Samama MM; Elalamy I
    Blood Coagul Fibrinolysis; 2004 Mar; 15(2):149-56. PubMed ID: 15091002
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of enoxaparin versus unfractionated heparin in patients with ST-segment elevation myocardial infarction also treated with clopidogrel.
    Sabatine MS; Morrow DA; Dalby A; Pfisterer M; Duris T; Lopez-Sendon J; Murphy SA; Gao R; Antman EM; Braunwald E;
    J Am Coll Cardiol; 2007 Jun; 49(23):2256-63. PubMed ID: 17560290
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mesenteric ischemia-reperfusion injury: clearly improved hemodynamics but only minor protection of the rat small intestine by (sub)therapeutic heparin sodium and enoxaparin doses.
    Walensi M; de Groot H; Schulz R; Hartmann M; Petrat F
    J Surg Res; 2013 Jan; 179(1):e57-69. PubMed ID: 22494914
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the anticoagulant intensities of fondaparinux and enoxaparin in the Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS)-5 trial.
    Anderson JA; Hirsh J; Yusuf S; Johnston M; Afzal R; Mehta SR; Fox KA; Budaj A; Eikelboom JW
    J Thromb Haemost; 2010 Feb; 8(2):243-9. PubMed ID: 19943881
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Edoxaban administration following enoxaparin: a pharmacodynamic, pharmacokinetic, and tolerability assessment in human subjects.
    Zahir H; Matsushima N; Halim AB; He L; Zhang G; Lee F; Worland V; Mendell J
    Thromb Haemost; 2012 Jul; 108(1):166-75. PubMed ID: 22628060
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adding intravenous unfractionated heparin to standard enoxaparin causes excessive anticoagulation not detected by activated clotting time: results of the STACK-on to ENOXaparin (STACKENOX) study.
    Drouet L; Bal dit Sollier C; Martin J
    Am Heart J; 2009 Aug; 158(2):177-84. PubMed ID: 19619692
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost effectiveness of enoxaparin as prophylaxis against venous thromboembolic complications in acutely ill medical inpatients: modelling study from the hospital perspective in Germany.
    Schädlich PK; Kentsch M; Weber M; Kämmerer W; Brecht JG; Nadipelli V; Huppertz E
    Pharmacoeconomics; 2006; 24(6):571-91. PubMed ID: 16761905
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Efficacy and Safety of Enoxaparin: A Meta-analysis.
    Hai-Long W; Xiao-Hua P; Jian-Jun Y
    Open Med (Wars); 2018; 13():359-365. PubMed ID: 30211318
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histones Differentially Modulate the Anticoagulant and Profibrinolytic Activities of Heparin, Heparin Derivatives, and Dabigatran.
    Ammollo CT; Semeraro N; Carratù MR; Colucci M; Semeraro F
    J Pharmacol Exp Ther; 2016 Feb; 356(2):305-13. PubMed ID: 26578266
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.